#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Endocrine ophthalmopathy Chronic myeloid leukaemia (in remission) Oesophageal adenocarcinoma stage II Hypomagnesaemia Neurodegenerative disorder Pulmonary tuberculosis Osteosarcoma Small cell lung cancer recurrent Meningitis meningococcal Chondrosarcoma metastatic Mantle cell lymphoma refractory Corneal neovascularisation Hereditary motor and sensory neuropathy Squamous cell carcinoma of head and neck Pyoderma gangrenosum More trials…

    Learn about Rare Diseases

    Metachromatic leukodystrophy – Trials in Disease Haemophilia A with anti factor VIII – Basic Information Synovial sarcoma recurrent – Trials in Disease Leiomyosarcoma recurrent – Diagnostics Retinoblastoma – Diagnostics Mucous membrane pemphigoid Mucopolysaccharidosis I – Treatment Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Life with Disease Kearns-Sayre syndrome – Treatment Hairy cell leukaemia – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sumatriptan Succinate Gozetotide Difelikefalin Tipapkinogene Sovacivec FOSFOMYCIN CALCIUM Vosilasarm Carbasalate Calcium Thiamazole Isotretinoin RIMIDUCID Flutemetamol (18F) Saxagliptin Entrectinib R-Azasetron Besilate Adezunap Argon Norucholic Acid Omp64 Human Normal Immunoglobulin Peboctocogene Camaparvovec More therapies…

    Learn about Your Condition

    Cardiac disorder Osteoarthritis Ebola disease Magnetic resonance imaging White matter lesion Idiopathic pulmonary fibrosis Premature rupture of membranes Liver transplant Frontotemporal dementia Metastatic glioma Hereditary angioedema Cerebral haemorrhage Pemphigus Lymphangioma Lupus nephritis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Medical Center Berbatov Ltd.

Medical Center Berbatov Ltd.

Ulitsa Beli Drin 9, Yambol, 8600, Bulgaria

Want to learn more about this study or check if you can participate? Contact us.

  • Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

    Recruiting

    3 1 1
    Investigated Drugs:
    • Efgartigimod Alfa
    Belgium Bulgaria Czechia Denmark France Germany +8

  • A Phase III Randomized Double‑Blind Study of Elecoglipron for Adults with Type 2 Diabetes on Insulin

    Recruiting

    3 1
    Investigated Drugs:
    • Azd5004
    Bulgaria Czechia Germany Poland

  • Long-Term Study of Imeroprubart in Adults With Graves’ Disease

    Recruiting

    2 1 1
    Investigated Diseases:
    • Graves’ disease
    Investigated Drugs:
    • IMEROPRUBART
    Belgium Bulgaria Czechia Germany Greece Hungary +5

  • Study of KAI-9531 in Adults With Obesity or Overweight and Weight-Related Health Problems Without Diabetes

    Recruiting

    3 1
    Investigated Drugs:
    • HRS 9531
    Bulgaria Czechia Germany Hungary Poland Spain

  • A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    • Chronic kidney disease
    Austria Belgium Bulgaria Czechia Estonia France +10

  • Study of IMVT-1402 Treatment for Adults with Graves’ Disease

    Recruiting

    2 1
    Investigated Drugs:
    • IMEROPRUBART
    Bulgaria Czechia Germany Greece Italy Latvia +3

  • Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Chronic kidney disease
    Investigated Drugs:
    • Azd5004
    • Dapagliflozin
    Bulgaria Czechia Denmark Finland France Germany +8

  • A Phase III Study of Elecoglipron Compared with Semaglutide for Adults with Type 2 Diabetes Mellitus

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Azd5004
    • Semaglutide
    Bulgaria Germany Hungary Italy Poland

  • Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

    Not yet recruiting

    3 1
    Investigated Drugs:
    • Maridebart Cafraglutide
    Bulgaria Czechia Germany Hungary Italy Poland

  • Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Insulin Glargine
    Bulgaria Czechia Germany Greece Italy Poland +1
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!